Apollo Endosurgery announces Saudi approval of ORBERA365
Apollo Endosurgery announced that the Saudi Food and Drug Authority has approved the ORBERA365 Managed Weight Loss System and has issued a Medical Device Marketing Authorization for the product. This MDMA allows Apollo Endosurgery to market ORBERA365 in the Kingdom of Saudi Arabia with its exclusive distribution partner, AL-Nozha Medical. The ORBERA365 Managed Weight Loss System doubles the indwell period of the #1 intragastric balloon in the world from 6 months to a 12 month treatment period. "Patients are looking for longer term endoscopic weight loss treatments. ORBERA365 now provides patients a greater probability of losing more weight and keeping it off. The additional 6 months gives us more time with the patient to ensure better outcomes," said Aayed AlQahtani, Professor of Surgery at King Khalid University Hospital and Director of Obesity Chair at King Saud University, Riyadh, Saudi Arabia. This approval expands the reach of ORBERA365 into the largest bariatric market in the Middle East with over 15,000 procedures performed per year.